Table 1.
Tissue-protective therapy by provision of IL-22, in rodent disease models
| Organ | IL-22 treatment | Observed effect | Reference |
|---|---|---|---|
| Lung | Single inhalation of recombinant IL-22 (10 μg·kg−1) | Attenuation of ventilator-induced lung injury | Hoegl et al., 2011 |
| Lung | 3 intranasal doses of recombinant IL-22 (1 μg per mouse on days 14, 15, and 16 during antigen challenge) | Protection from lung inflammation in the OVA model | Besnard et al., 2011 |
| Lung | 2 intranasal doses of recombinant IL-22 (0.1 μg per mouse, 48 and 2 h before OVA challenge) | Amelioration of allergic airway inflammation in the OVA model | Takahashi et al., 2011 |
| Lung | Single intranasal dose of recombinant IL-22 (0.1, 1 or 10 μg per mouse, 1 h before OVA challenge) | Amelioration of allergic airway inflammation in the OVA model | Taube et al., 2011 |
| Lung | Intratracheal treatment with recombinant IL-22 (100 pg and 100 ng per mouse, 3×/week for 4 weeks) | Protection from lung fibrosis in the Bacillus subtilis model | Simonian et al., 2010 |
| Liver | Single i.v. dose of recombinant IL-22 (3.5 μg per mouse) | Attenuation of acetaminophen (paracetamol)-induced liver damage | Scheiermann et al., 2013 |
| Liver | IL-22 transgenic mice; administration of Ad-IL-22 | Anti-fibrotic role of IL-22 in the liver | Kong et al., 2012 |
| Liver | Single i.v. dose of recombinant IL-22 (5 μg per mouse) | Protection from hepatic ischaemia-reperfusion injury | Chestovich et al., 2012 |
| Liver | Daily doses of recombinant IL-22 (0.5 μg per mouse) for 7 days | Anti-fibrotic role of IL-22 in the liver | Meng et al., 2012 |
| Liver | Single i.v. dose of recombinant IL-22 (0.5 μg·g−1) | Protection from hepatic injury induced by LPS plus D-galactosamine | Xing et al., 2011a |
| Liver | Daily i.v. dose of recombinant IL-22 (0.5 mg·kg−1) | Protection from liver injury after acute alcohol intoxication | Xing et al., 2011b |
| Liver | IL-22 transgenic mice | Enhanced tumour formation; protection from ConA-induced liver damage; accelerated liver regeneration after partial hepatectomy | Park et al., 2011 |
| Liver | Single i.p. dose of recombinant IL-22 (1 μg·g−1) | Protection from liver injury after chronic alcohol feeding | Ki et al., 2010 |
| Liver | Daily i.p. doses of recombinant IL-22 (300 μg·kg−1) for 36 days; in ob/ob mice daily s.c. doses of recombinant IL-22 (500 μg·kg−1) for 14–40 days | Protection from high fat diet-induced steatosis | Yang et al., 2010 |
| Liver | In vivo IL-22 cDNA delivery | Protection from ConA-, carbon tetrachloride-, and Fas-induced liver damage | Pan et al., 2004 |
| Liver | Single i.v. dose of recombinant IL-22 (0.25 μg·g−1) | Protection from ConA-induced liver damage | Radaeva et al., 2004 |
| Intestinal tract, liver, spleen | Repeated i.p. doses of recombinant IL-22 (25 μg per mouse, every other day starting on day 0) | Protection from systemic translocation of commensal intestinal bacteria in the context of impaired innate lymphoid cell function | Sonnenberg et al., 2012 |
| Intestinal tract | Repeated i.p. doses of recombinant IL-22-Fc fusion protein (0.05 mg per mouse) on days 0, 3, and 6 | Protection from severe DSS-induced colitis | Cox et al., 2012 |
| Intestinal tract | In vivo delivery of an IL-22-expressing plasmid | Protection from severe infection by Citrobacter rodentium | Qiu et al., 2012 |
| Intestinal tract | In vivo delivery of an IL-22-expressing plasmid | Protection from severe infection by Citrobacter rodentium | Tumanov et al., 2011 |
| Intestinal tract | In vivo delivery of an IL-22-expressing plasmid | Protection from Th2-mediated colitis in the TCRα-KO model | Sugimoto et al., 2008 |
| Pancreas | In vivo delivery of adenovirus-IL-22; single i.p. dose of recombinant IL-22 (1 μg·g−1); IL-22 transgenic mice | Attenuation of cerulein-induced pancreatitis | Feng et al., 2012 |
| Pancreas | Single i.p. dose of recombinant IL-22 (200 ng per mouse) 24 h after onset of pancreatitis | Protection from pancreatitis induced by either cerulein or choline-deficient diet supplemented with DL-ethionine | Xue et al., 2012 |
ConA, concanavalin A; DSS, dextran sulfate sodium; OVA, ovalbumin; TCRα; T-cell receptor α-chain.